Across TCGA pan-cancer cohorts, PRYP2 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated PRYP2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRYP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRYP2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, CESC, and LUAD are the cancer types where PRYP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.166	0.616	.043	18	view →
CESC	OS	Tertile	All	0.271	0.798	.010	18	view →
LUAD	OS	Tertile	All	0.211	0.697	.005	18	view →
STAD	OS	Tertile	All	0.884	0.642	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRYP2 tumor-vs-normal RNA expression · all PRYP2 data types